Ovid Therapeutics Inc.
For the period ended Mar 17, 2026. Filed Mar 18, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 17, 2026 · Filed Mar 18, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · Phase 2 dose confirmatory & open-label proof-of-concept study
Phase 2 dose confirmatory & open-label proof-of-concept study
Ovid believes the drug exposure, PK, safety, and tolerability profile observed with the 5 mg and 7 mg doses of OV329 are supportive of further clinical development and provide dose optionality for planned Phase 2 proof-of-concept and dose confirmatory studies. Ovid plans to initiate an open-label photo paroxysmal response study to evaluate the anti-seizure effect of OV329. In parallel, the Company is advancing plans for a Phase 2 randomized, placebo-controlled trial, which is expected to evaluate two dose levels and determine seizure reduction efficacy in people living with treatment-resistant FOS. Ovid is engaged in regulatory conversations and currently anticipates initiating the Phase 2 study in the second quarter of 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.